Uveal Melanoma Metastases
Uveal Melanoma Metastases - Related Videos
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
0 Views •
Cited by 23 •
2015
Here, we present a protocol how to perform an isolated liver perfusion (IHP) with melphalan and we also discuss IHP as a treatment option for liver metastases of uveal melanoma.
04:02
Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice
0 Views •
Cited by 7 •
2019
Orthotopic human liver metastatic uveal melanoma xenograft mouse models were created using surgical orthotopic implantation techniques with patient-derived tumor chunk and needle injection techniques with cultured human uveal melanoma cell lines.
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
0 Views •
Cited by 12 •
2016
In this manuscript, we describe percutaneous isolated hepatic perfusion with simultaneous chemofiltration as treatment for unresectable liver metastases. This procedure is performed under general anaesthesia in the angiosuite by an experienced team, consisting of an interventional radiologist, a clinical perfusionist and anaesthesiologist.
03:52
Experimental Metastatic Melanoma Mouse Model: A Platform to Study the Metastatic Potential of Melanoma Cells in the Lungs
0 Views •
2023
In this video, melanoma cells are intravenously injected through the tail vein in the mouse model. The melanoma cells further travel through the circulatory system, adapting to the distant microenvironment and causing metastasis in organs like lungs.
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
FAQs
Dissemination occurs primarily through the bloodstream, allowing melanoma cells originating in the eye’s uveal tract to travel beyond the primary tumor. This route helps explain why metastatic disease can appear in organs distant from the eye rather than remaining confined to nearby tissues. Understanding hematogenous spread is important when planning surveillance and evaluating the risk of systemic disease.
The liver has a strong tendency to support colonization by disseminated uveal melanoma cells. After arriving through the circulation, these cells interact with the local tissue environment and may establish new tumor growth. Studying this interaction helps explain organ-specific metastatic patterns and supports investigation of treatments designed specifically to address liver involvement.
Molecular drivers can influence how uveal melanoma cells disseminate, survive, and establish tumors in distant tissues. Tumor–immune interactions also affect the environment in which metastatic disease develops. Examining both dimensions provides a broader biological view than tracking tumor location alone and informs research into targeted treatments and systemic immunotherapy.
Researchers examine how disseminated melanoma cells interact with the tissues they enter, particularly the liver environment. This approach focuses on the relationship between tumor cells and surrounding local conditions rather than treating metastasis as cell movement alone. Findings can clarify why certain organs support tumor establishment and can guide liver-directed or systemic therapeutic strategies.
Surveillance is used to assess metastatic risk and look for disease before it becomes clinically advanced. The overview identifies early detection as an important research and clinical goal, especially because metastatic spread drives much of the mortality associated with this cancer. Monitoring information can contribute to decisions about follow-up intensity and treatment selection.
Liver-directed therapies are investigated because the liver is the principal organ associated with metastatic colonization in uveal melanoma. Their development reflects the need to address disease within its specific tissue environment, rather than relying only on approaches directed at the original ocular tumor. This area remains part of broader research into controlling advanced metastatic disease.
Risk assessment helps organize clinical decisions around the likelihood and pattern of systemic disease. Information about metastatic behavior, molecular drivers, immune interactions, and liver involvement can support selection among surveillance, liver-directed therapies, systemic immunotherapy, or targeted treatments. The goal is to align management with disease biology and to identify progression as early as possible.
Research includes liver-directed therapies, systemic immunotherapy, and targeted treatments. These approaches address different aspects of metastatic disease: the dominant organ site, the immune relationship with the tumor, and molecular factors that drive progression. Studying them together supports treatment selection and reflects the need for strategies that can manage disease beyond the original eye tumor.